A smart card-enabled Cholesterol Monitor will be available to consumers by year-end pending FDA approval, the Post Falls, Idaho-based company says. The device uses one drop of blood to determine cholesterol levels in three minutes; the results are then encrypted and downloaded on the included Privalink Microsoft Smart Card for Windows, allowing them to be sent to doctors or pharmacists via the Internet; the data also can be delivered in person. Other software records cholesterol levels for later review. Print advertising and an infomercial will promote the product to consumers and professionals, who must cooperate in establishing an information system to receive and store the data. The monitor will retail for $129.95, with packets of six test kits selling for $19.95
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
US FDA would receive more funding for fiscal year 2026 in the Senate appropriations bill than its House counterpart, including $10m for unannounced foreign inspections.
A new EU strategy to ensure access to essential medicines will boost the development of critical medical counter measures, including vaccines and therapies, according to one pharmaceutical industry group.
In this first of a two-part series of articles, US Pharmacopeia CEO Ronald T. Piervincenzi tells the Pink Sheet how the use of alternatives to animal testing in drug development is gaining traction and discusses the challenges that exist.
